GANYMED PHARMACEUTICALS AG;TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemein-nützige GmbH
发明人:
Ugur Sahin,Özlem Türeci
申请号：
US14777231
公开号：
US10137195B2
申请日:
2014.03.17
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
